- Dr. Lawrence Shulman led the effort in determining which cancer drugs should be included in the World Health Organization's List of Essential Medicines.
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center has joined a Memorial Sloan Kettering clinical trial of immunotherapy for children with relapsed or treatment-resistant acute lymphoblastic leukemia. Dana-Farber/Boston Children’s is the only site in New England to offer this breakthrough experimental approach that triggers a patient's immune system to attack cancer cells.
Tags: ChildhoodCancer, Immunotherapy
- New research suggests that cholesterol-lowering statin drugs could be a valuable addition to current therapies for prostate cancer.
- After identifying three different types of resistance to a promising investigational lung cancer drug, a team of researchers led by Dana-Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors’ constant and varied molecular shape-shifting.
- A study led by Pasi Jänne, MD, PhD, found that an experimental drug targeted to the resistance mutation is highly active in patients with EGFR-positive non-small cell lung cancer (NSCLC) when the disease progressed during treatment with front-line inhibitor drugs.
Tags: LungCancer, Genetics
- Bruce Spiegelman, PhD, Dana-Farber Cancer Institute, has received Belgium's most important international scientific prize for his contributions to understanding the mechanisms of metabolic disorders.
Tags: BasicResearch, Honors
- In a new study, researchers at Dana-Farber Cancer Institute show that disruptions to the activity of cell proteins can reveal which genetic mutations lead to disease and which are mere bystanders.
- Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health in Boston and the Irish Cancer Society have formed the Boston-Ireland Prostate Cancer Collaboration. This new entity will conduct and facilitate exchanges of researchers and knowledge between Boston and Ireland.
Tags: BasicResearch, ProstateCancer
- Dana-Farber researchers report that combination treatment with olaparib and BKM120 was safe and yielded evidence of clinical benefit for women with triple-negative breast cancer and for those with high-grade serous ovarian cancer in a phase I clinical trial.
Tags: OvarianCancer, TranslationalResearch
- Dana-Farber researchers report in the New England Journal of Medicine that treating advanced melanoma patients initially with the combination of the immunotherapy drugs nivolumab and ipilimumab achieves a much higher response rate than treatment with ipilimumab alone.
Tags: Melanoma, Immunotherapy
Showing 11-20 of 599 items